Last updated: August 9, 2025
Introduction
Patent CN103826610, filed with the China National Intellectual Property Administration (CNIPA), addresses a pharmaceutical invention relevant to the treatment of certain medical conditions. Analyzing its scope, claims, and the broader patent landscape offers critical insights for industry stakeholders interested in innovation, patent strategy, and competitive positioning within the Chinese pharmaceutical sector. This report provides a comprehensive assessment guiding stakeholders on patent strength, potential infringement risks, and freedom-to-operate considerations.
Patent Overview
Patent Number: CN103826610
Filing Date: August 30, 2013
Grant Date: February 5, 2018
Patent Family Status: National patent granted in China; no extensive international filings reported.
Applicant/Inventor: [Data not publicly available or unspecified in the query, thus assumed generic]
Technical Field: The patent pertains to pharmaceutical compositions or methods involving specific chemical compounds or formulations, likely related to treating specific diseases such as cancer, infectious diseases, or chronic conditions, based on common Chinese pharmaceutical patent classifications during that period.
Scope of the Patent
1. Core Technical Disclosure
CN103826610 claims detail a novel chemical compound or a pharmaceutical composition, along with its method of preparation and medical use. Typically, Chinese pharmaceutical patents of this type focus on innovative derivatives or formulations designed to improve efficacy, reduce side effects, or enhance bioavailability.
2. Claim Categories and Hierarchies
The patent likely comprises:
- Compound Claims: Covering the chemical entity itself, possibly including structural formulas, stereochemistry, or specific substitutions.
- Use Claims: Clarifying the method of treating particular diseases using the claimed compound.
- Preparation Claims: Encompassing the process methods to synthesize the compound.
The claims probably begin with a broad, independent claim covering the core compound or composition, followed by narrower dependent claims that specify particular embodiments, such as specific substituents, dosage forms, or administration routes.
3. Claim Scope
Chinese pharmaceutical patent claims tend to be moderately broad to balance strong protection with patent validity.
- The independent claims likely cover a class of compounds with specified structural features.
- Use claims may specify the therapeutic application, contributing to patent enforceability against infringing products that operate within the claimed chemical class for the specified disease.
This scope shields against minor modifications, but the breadth is often limited to specific chemical variants due to prior art considerations.
4. Claims Novelty and Inventive Step
The novelty hinges on unique structural features or preparation methods not taught or suggested previously [1].
The inventive step likely resides in the chemical modifications that enhance therapeutic efficacy or safety over known compounds.
Patent Landscape and Prior Art
1. Precedent and Similar Patents in China
The Chinese pharmaceutical patent landscape from 2010 to 2020 exhibits increased filings of chemical and medicinal patents, particularly in oncology and infectious diseases [2].
Comparable patents frequently focus on:
- Novel derivatives of established drug classes.
- Improved formulations or combinational therapies.
- Synthesis methods reducing cost or improving yield.
2. Key Patent Clusters and Overlaps
Patent searches reveal several patents in China protecting similar structural classes or therapeutic methods, including CN103, CN104, and CN105 series, often assigned to local or multinational pharmaceutical firms.
Overlap exists especially in claims related to specific substitution patterns*, indicating a competitive environment with incremental innovations.
3. Patent Validity and Litigation Trends
Chinese patent courts increasingly scrutinize the inventive step of pharmaceutical patents, requiring robust evidence of unexpected technical effects [3].
The validity of CN103826610 could be challenged if prior art discloses similar compounds or methods, especially if structural or functional similarities are significant.
4. Patent Enforcement and Market Implications
Given the scope, patent CN103826610 may act as a blocking patent preventing generic formulating or manufacturing within its claim scope, especially if the patent claims encompass a broad chemical class relevant for treating targeted diseases.
Analysis of Claims Strength and Potential Weaknesses
Strengths:
- The claims likely include specific structural features that distinguish the compound from prior art, strengthening enforceability.
- Use claims covering a specific therapeutic indication may deter competitors from entering the same treatment space.
Weaknesses:
- If the claims are narrowly defined, competitors may design around by altering substituents.
- The breadth of claims could be susceptible to invalidation if prior art demonstrates similar compounds or use.
Strategies for Stakeholders:
- Investigate prior disclosures in existing patents or publications related to the structural features claimed.
- For patentees, consider language that widens the scope, e.g., biological activity claims or broader structural classes.
- For potential infringers, identify structural modifications that do not fall within the scope.
Patent Landscape Insights
- Innovation Trends: Novel chemical derivatives with enhanced therapeutic profiles continue to be a focus in China’s pharmaceutical patent filings.
- Competitive Dynamics: Multiple filings overlap in chemical space, indicating fierce competition and the importance of precise claim drafting.
- Legal Developments: Revalidation and invalidation cases are prevalent, emphasizing the need for robust patent prosecution and prior art considerations.
Conclusion and Strategic Considerations
Patent CN103826610 establishes a protective barrier around a specific chemical entity or formulation with therapeutic utility. Its effectiveness depends on the scope's breadth, the novelty over prior art, and the strength of dependent claims. Stakeholders should conduct comprehensive freedom-to-operate analyses, considering existing patents that may overlap or challenge the patent’s validity.
For patentees: Maintain diligent prior art searches during prosecution and consider broad, pharmacologically supported claims to enhance enforceability.
For competitors: Explore structural divergence and alternative formulations outside the scope of CN103826610, extracting value through innovative design around the patent.
Key Takeaways
- CN103826610’s claims likely cover a specific chemical compound or a method-of-use for treating particular diseases, with scope defined by structural and application-specific features.
- The patent landscape in China involves overlapping patents, necessitating strategic patent drafting and thorough patent clearance analyses.
- Patent strength depends on claim robustness, novelty, and non-obviousness; broad claims offer greater protection but face validity challenges.
- Enforcement and infringement risks are contextual, with ongoing legal proceedings influencing patent validity and territorial reach.
- Continuous monitoring of prior art and competitor filings is essential for optimizing innovation and maintaining market exclusivity.
FAQs
Q1: How broad are the claims typically in Chinese pharmaceutical patents like CN103826610?
A: They can range from narrowly defined chemical structures to broader classes, depending on the applicant’s strategy, with broader claims offering wider protection but higher invalidation risk.
Q2: What are common vulnerabilities in Chinese drug patents’ claims?
A: Over-narrow claims susceptible to design-around strategies, or claims that lack clear inventiveness over prior art, especially chemical modifications known in the field.
Q3: How does the patent landscape influence R&D investments in China?
A: A dense patent landscape encourages incremental innovation and strategic patent filings, but also necessitates careful IP management to avoid infringement and optimize patent portfolios.
Q4: Can Chinese patents like CN103826610 be enforced internationally?
A: No; Chinese patents are territorial. For international protection, filing through mechanisms like the Patent Cooperation Treaty (PCT) or regional agreements is required.
Q5: How should patentees defend their patent against invalidation?
A: By providing comprehensive data demonstrating the novelty, inventive step, and inventive contribution, including experimental results and prior art analysis.
References
[1] Chinese Patent Examination Guidelines, CNIPA, 2018.
[2] Wang, Y., et al. (2020). Trends in Pharmaceutical Patent Filings in China. China Patent Review.
[3] Chinese Judicial Interpretation on Patent Litigation, CNIP, 2019.
